

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Noriaki Ishida, Corporate Officer,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

<http://www.daiichisankyo.com>

Daiichi Sankyo Completes Integration of Odawara Plants of Japan Supply Chain Subsidiaries

Tokyo, Japan (April 1, 2013) – DAIICHI SANKYOCOMPANY, LIMITED (hereafter, Daiichi Sankyo) today announced that it has completed the integration of the Odawara plants of its Japanese supply chain subsidiaries, DAIICHI SANKYO PROPHARMA CO., LTD. (hereafter, DSPP) and DAIICHI SANKYO CHEMICAL PHARMA CO., LTD. (hereafter, DSCP) as previously announced in the October 1, 2012, news release entitled, “Daiichi Sankyo to Reorganize Japanese Supply Chain Subsidiaries and Integrate their Odawara Plants.”

1. Objective of integration

The two neighboring plants have been integrated in order to build a consistent system of manufacturing everything from intermediates to API while utilizing scientific research capabilities to enhance the manufacturing technology infrastructure and make Daiichi Sankyo structurally competitive on a global level.

2. Method of integration

As of today, the DSPP Odawara plant has been split off and absorbed into DSCP, which will act as the succeeding company through an Absorption-type Company Split as provided for in “The Companies Act of Japan.” Consequently, the neighboring DSPP and DSCP Odawara plants have been integrated.

3. Post-integration overview for the new plant

Plant name: DAIICHI SANKYO CHEMICAL PHARMA CO., LTD., Odawara Plant

Location: 477, Takada, Odawara, Kanagawa, Japan

Area: 133,000 m²

Plant manager: Yoshinobu Ohshima

Employees: Approximately 250

Main products: API and intermediates for pharmaceuticals (olmesartan medoxomil, loxoprofen sodium, etc.)

For Reference

Overview of DSPP and DSCP (as of April 1, 2013)

DAIICHI SANKYO PROPHARMA CO., LTD.

Head office: 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, Japan

Plants: Akita, Onahama, Hiratsuka, Tatebayashi, Takatsuki

Capital: 100 million yen (100% owned by Daiichi Sankyo)

Representative: Tsutomu Shimizu, Representative Director & President

Sales: 78 billion yen (fiscal year ending in March 2012)

Employees: Approximately 1,430

Main businesses: Manufacture and contract manufacture of pharmaceuticals, OTC drugs, and investigational drugs

DAIICHI SANKYO CHEMICAL PHARMA CO., LTD.

Head office: 4-4-8, Nishiyawata, Hiratsuka, Kanagawa, Japan

Plants: Hiratsuka, Odawara

Capital: 50 million yen (100% owned by Daiichi Sankyo)

Representative: Akihiko Miyadera, Representative Director & President

Sales: 9.9 billion yen (fiscal year ending in March 2012)

Employees: Approximately 480

Main businesses: Manufacture and contract manufacture of API and intermediates for pharmaceuticals